<DOC>
	<DOCNO>NCT02104817</DOCNO>
	<brief_summary>The study randomize , double-blind , placebo-controlled ( corn oil ) , parallel group design enroll approximately 13,000 patient hypertriglyceridemia low HDL high risk CVD randomize 1:1 either corn oil + statin Epanova + statin , daily , approximately 3-5 year determine number MACE outcomes reach .</brief_summary>
	<brief_title>Outcomes Study Assess STatin Residual Risk Reduction With EpaNova HiGh CV Risk PatienTs With Hypertriglyceridemia</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Hydroxymethylglutaryl-CoA Reductase Inhibitors</mesh_term>
	<criteria>1 . Men woman , ≥18 year age . 2 . Patient must stable diet statin* therapy least 4 week prior randomization ( Visit 2 ) meet follow criterion : 1 . LDLC &lt; 100 mg/dL 2 . TG level ≥180 &lt; 500 mg/dL HDLC &lt; 42 mg/dL men HDLC &lt; 47 mg/dL woman 3 . Patient high risk future cardiovascular event least one follow criterion ( 3a , 3b 3c ) * present via patient history , physical exam , medical record time screening : 1 . Any atherosclerotic CVD define protocol . 2 . History diabetes mellitus ( type 1 2 ) ≥40 year age men ≥50 year age woman , plus one risk factor define protocol . 3 . Male patient &gt; 50 year age females &gt; 60 year age , least one risk factor define protocol . Key 1 . Allergy intolerance omega3 carboxylic acid , omega3 fatty acid , omega3acid ethyl ester , corn oil . 2.Use fibrates , bile acid sequestrants , niacin analogue ( &gt; 250 mg/day ) within 4 week prior Visit 2 . 3.Statin naïve Visit 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>omega-3 carboxylic acid</keyword>
</DOC>